Rigel Pharmaceuticals, Inc. (RIGL)

Over the past six months, Rigel Pharmaceuticals' stock has declined by 25.36%, and year-to-date, it is down 38.40%, but it rose by 38.73% over the last 12 months. Key events include Q1 2026 financial results with net product sales of just under $55 million, a 26% increase compared to the first quarter of 2025, Q4 and full year 2025 financial results with preliminary total revenue for Q4 2025 was approximately $69.8 million, with net product sales of $65.4 million, publication of GAVRETO clinical data in the Journal of Clinical Oncology, inducement grants to non-executive employees, a stock price increase in November 2025 benefiting institutional investors, and a capital raise in late 2024 to finance the expansion of the IRAK1/4 program.

Demand for Rigel Pharmaceuticals' products exhibits seasonality, with the first quarter typically impacted by reimbursement dynamics, affecting January and February volumes. Demand tends to improve in March, leading to stronger volumes across the company's product portfolio, and Rigel anticipates a return to sequential growth starting in the second quarter.

Rigel Pharmaceuticals is focused on developing small-molecule drugs for autoimmune, cancer-related, and viral diseases. Its major marketed products include TAVALISSE for chronic immune thrombocytopenia (ITP), REZLIDHIA for mIDH1 acute myeloid leukemia, and GAVRETO for RET fusion-positive non-small cell lung cancer (NSCLC). The company's pipeline includes R289, an interleukin receptor-associated kinase (IRAK1/4) inhibitor in Phase 1b study for lower-risk myelodysplastic syndrome, and Ocadusertib, which is being developed in collaboration with Eli Lilly.

Rigel Pharmaceuticals is headquartered in South San Francisco, California, United States. The company collaborates with partners to bring its products to markets outside of the U.S.

Rigel Pharmaceuticals' reputation is inferred from its positive financial and clinical developments, including a 26% year-over-year increase in Q1 2026 sales across its product portfolio, the publication of final ARROW clinical trial data for GAVRETO, and the company's consistent guidance towards achieving net income profitability in 2026.

Rigel Pharmaceuticals' ownership is predominantly institutional, with institutional shareholders holding between 85% and 87.53% of the company's shares. Major institutional owners include BlackRock, Inc., State Street Corp, and Vanguard Group Inc. Bvf Partners L P is the largest individual shareholder, owning 16.66 million shares, representing 90.19% of the company. James E. Flynn also holds a significant individual stake of 36.50%, or 6.74 million shares. Insiders, including CEO Raul Rodriguez, own a smaller percentage of shares, and no single shareholder holds a majority interest in the company.